Science

Rahul Banerjee: CEPHEUS by Saad Z. Usmani, et al is out

Rahul Banerjee and Saad Z. Usmani

Feb 7, 2025, 08:39

Rahul Banerjee: CEPHEUS by Saad Z. Usmani, et al is out

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Saad Z. Usmani, et al. on X:

“CEPHEUS out!

Congratulations Saad Z. Usmani, et al.

PFS with quad in ASCT MMsm. Nice discussion of similarities (many) & differences (few) vs IMROZ.

CD38-VRd now the norm for many: time to shift algorithms to quad-eligible vs not regardless of ASCT plans!”

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study.

Authors: Saad Z. Usmani, et al.

Rahul Banerjee: CEPHEUS by Saad Z. Usmani, et al is out

Bortezomib cancer CD38-VR CEPHEUS Daratumumab dexamethasone fight against cancer Fred Hutchinson Cancer Center Global fight against cancer IMROZ Lenalidomide multiple myeloma OncoDaily Oncology Rahul Banerjee Saad Z. Usmani University of Washington

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer

Oncologist Near Me - Matti Aapro: Pioneering Excellence in Cancer Care and Geriatric Oncology

World Cancer Day: 25 Years of Global Action and Unity in the Fight Against Cancer

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research